Felzartamab
As of the edition of 20 October 2026, Felzartamab is an antibody: in active development; acts on CD38.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 15, 1 stopped early
- Disease areas
- Immune system; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Felzartamab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | P28907 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 8 | 6 | 2 | 0 |
| Phase 3 | 5 | 1 | 4 | 0 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Morphosys | Lead sponsor of trials | 2011 to now |
| TJ Biopharma | Lead sponsor of trials | 2019 to now |
| Biogen | Lead sponsor of trials | 2019 to now |